PL EN


Preferences help
enabled [disable] Abstract
Number of results
2016 | 16 | 3 | 155–159
Article title

Zmiany sprawności funkcji poznawczych w trakcie suplementacji wielonienasyconymi kwasami tłuszczowymi omega-3 w grupie chorych na schizofrenię – przegląd systematyczny

Content
Title variants
EN
Changes in cognitive performance during supplementation with omega-3 polyunsaturated fatty acids in patients with schizophrenia – a systematic review
Languages of publication
EN PL
Abstracts
EN
Cognitive function deficit is a constant phenomenon described in the population of patients with schizophrenia – in the premorbid period, during exacerbations and between the successive episodes. Cognitive dysfunction is an independent prognostic factor in schizophrenia. Studies indicate that this pathology dimension affects patient-functioning indicators, such as: treatment and rehabilitation outcomes, cooperation during treatment, professional, family and social functioning, the ability to live independently as well as the quality of life. Current methods for the treatment of schizophrenia fail to ensure sufficient improvement in this dimension of the disease. The usefulness of omega-3 polyunsaturated fatty acids, both as a monotherapy and an augmentation of antipsychotic treatment in schizophrenia, has been investigated during the last 25 years. The obtained results are inconclusive, however, a positive tendency in the outcomes related to symptomatic improvement have been observed. The effects of omega-3 polyunsaturated fatty acid supplementation on the cognitive functioning of patients diagnosed with schizophrenia has been relatively rarely evaluated. However, there is a theoretical rationale for the beneficial effect of omega-3 polyunsaturated fatty acid supplementation on cognitive function. The known effects of these substances that could contribute to the improvement in cognitive function include: immunomodulatory effects in the CNS, improvement of oxidative stress parameters, changes in neurotransmission as well as effects on neuroplasticity. The aim of this paper is to present a systematic review of research findings on the changes in cognitive performance in patients diagnosed with schizophrenia who receive omega-3 polyunsaturated fatty acid supplementation.
PL
Deficyt w obszarze funkcjonowania poznawczego jest stałym fenomenem opisywanym w populacji osób z rozpoznaniem schizofrenii – w okresie przedchorobowym, w trakcie pogorszeń, jak również między kolejnymi epizodami. Zaburzenie funkcjonowania poznawczego stanowi niezależny czynnik rokowniczy w schizofrenii. Badania wskazują, że właśnie od tego wymiaru patologii zależą takie wykładniki funkcjonowania pacjentów, jak: wyniki leczenia i rehabilitacji, współpraca w leczeniu, funkcjonowanie zawodowe, rodzinne i społeczne, zdolność do samodzielnej egzystencji oraz jakość życia. Dotychczasowe metody leczenia schizofrenii nie zapewniają wystarczającej poprawy w zakresie tego wymiaru choroby. W okresie ostatnich 25 lat testowano użyteczność wielonienasyconych kwasów tłuszczowych omega-3 jako monoterapii oraz jako augmentacji leczenia przeciwpsychotycznego w schizofrenii. Uzyskane wyniki są niejednoznaczne, choć podkreśla się tzw. pozytywny trend uzyskiwanych wyników w zakresie poprawy objawowej. Stosunkowo rzadko oceniano wpływ suplementacji preparatami wielonienasyconych kwasów tłuszczowych omega-3 na funkcjonowanie poznawcze osób z rozpoznaniem schizofrenii. Korzystny wpływ suplementacji wielonienasyconymi kwasami tłuszczowymi na funkcjonowanie poznawcze ma uzasadnienie teoretyczne. Wśród znanych działań tych substancji mogących wpływać na usprawnienie funkcji poznawczych należy wymienić: działanie immunomodulacyjne w obrębie ośrodkowego układu nerwowego, poprawę parametrów stresu oksydacyjnego, zmiany w zakresie neurotransmisji oraz wpływ na procesy plastyczności neuronalnej. Celem niniejszej pracy jest przedstawienie systematycznego przeglądu wyników badań dotyczących zmian sprawności funkcjonowania poznawczego u osób z rozpoznaniem schizofrenii będących w trakcie suplementacji wielonienasyconymi kwasami tłuszczowymi omega-3.
Discipline
Publisher

Year
Volume
16
Issue
3
Pages
155–159
Physical description
Contributors
  • Klinika Psychiatrii Młodzieżowej UM w Łodzi, ul. Czechosłowacka 8/10, 92-216 Łódź, martagrancow@gmail.com
  • Klinika Psychiatrii Młodzieżowej Uniwersytetu Medycznego w Łodzi, Łódź, Polska. Kierownik: prof. dr hab. n. med. Agnieszka Gmitrowicz
  • Klinika Zaburzeń Afektywnych i Psychotycznych Uniwersytetu Medycznego w Łodzi, Łódź, Polska. Kierownik: dr hab. n. med. Dominik Strzelecki
  • Klinika Zaburzeń Afektywnych i Psychotycznych Uniwersytetu Medycznego w Łodzi, Łódź, Polska. Kierownik: dr hab. n. med. Dominik Strzelecki
References
  • Aleman A, Agrawal N, Morgan KD et al.: Insight in psychosis and neuropsychological function: meta-analysis. Br J Psychiatry 2006; 189: 204–212.
  • Allott K, Liu P, Proffitt TM et al.: Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. Schizophr Res 2011; 125: 221–235.
  • Amminger GP, Schäfer MR, Papageorgiou K et al.: Long-chain ω-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146–154.
  • Bayard S, Capdevielle D, Boulenger JP et al.: Dissociating self-reported cognitive complaint from clinical insight in schizophrenia. Eur Psychiatry 2009; 24: 251–258.
  • Berger GE, Proffitt TM, McConchie M et al.: Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry 2007; 68: 1867–1875.
  • Bondi CO, Taha AY, Tock JL et al.: Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency. Biol Psychiatry 2014; 75: 38–46.
  • Fenton WS, Dickerson F, Boronow J et al.: A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158: 2071–2074.
  • Fusar-Poli P, Berger G: Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol 2012; 32: 179–185.
  • Fusar-Poli P, Deste G, Smieskova R et al.: Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 2012; 69: 562–571.
  • Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321–330.
  • Green MF, Kern RS, Heaton RK: Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004; 72: 41–51.
  • Heinrichs RW: The primacy of cognition in schizophrenia. Am Psychol 2005; 60: 229–242.
  • Heinrichs RW, Zakzanis KK: Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998; 12: 426–445.
  • Horrobin DF: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30: 193–208.
  • Innis SM: Dietary omega 3 fatty acids and the developing brain. Brain Res 2008; 1237: 35–43.
  • Irving CB, Mumby-Croft R, Joy LA: Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 2006; (3): CD001257.
  • Joffre C, Nadjar A, Lebbadi M et al.: n-3 LCPUFA improves cognition: the young, the old and the sick. Prostaglandins Leukot Essent Fatty Acids 2014; 91: 1–20.
  • Keefe RS, Buchanan RW, Marder SR et al.: Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull 2013; 39: 417–435.
  • Kern RS, Nuechterlein KH, Green MF et al.: The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry 2008; 165: 214–220.
  • Kim SW, Schäfer MR, Klier CM et al.: Relationship between membrane fatty acids and cognitive symptoms and information processing in individuals at ultra-high risk for psychosis. Schizophr Res 2014; 158: 39–44.
  • Knöchel C, Voss M, Grüter F et al.: Omega 3 fatty acids: novel neurotherapeutic targets for cognitive dysfunction in mood disorders and schizophrenia? Curr Neuropharmacol 2015; 13: 663–680.
  • Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee: Fish consumption, fish oil, omega-3 fattyacids, and cardiovascular disease. Circulation 2002; 106: 2747–2757.
  • Landrø NI, Bentsen H: The effects of a fatty acid and antioxidants on neuropsychological functioning in schizophrenia and related psychoses. Schizophr Bull 2007; 33: 529–530.
  • McGurk SR, Twamley EW, Sitzer DI et al.: A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007; 164: 1791–1802.
  • Medalia A, Bellucci D: Neuropsychologically informed interventions to treat cognitive impairment in schizophrenia. In: Marcopulos BA, Kurtz MM (eds.): Clinical Neuropsychological Foundations of Schizophrenia. Routledge, New York (NY) 2012: 275–302.
  • Mesholam-Gately RI, Giuliano AJ, Goff KP et al.: Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009; 23: 315–336.
  • Milev P, Ho BC, Arndt S et al.: Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162: 495–506.
  • Nuechterlein KH, Green MF, Kern RS et al.: The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008; 165: 203–213.
  • Proffitt T, Wood SJ, Monfries R et al.: Bioactive lipids and cognitive function in first-episode psychosis. Schizophr Res 2003; 60 (suppl. 1): 153.
  • Reddy R, Fleet-Michaliszyn S, Condray R et al.: Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: preliminary study. Prostaglandins Leukot Essent Fatty Acids 2011; 84: 79–83.
  • Schlögelhofer M, Amminger GP, Schaefer MR et al.: Polyunsaturated fatty acids in emerging psychosis: a safer alternative? Early Interv Psychiatry 2014; 8: 199–208.
  • Seidman LJ, Giuliano AJ, Meyer EC et al.; North American Prodrome Longitudinal Study (NAPLS) Group: Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 2010; 67: 578–588.
  • Sumiyoshi T, Matsui M, Itoh H et al.: Essential polyunsaturated fatty acids and social cognition in schizophrenia. Psychiatry Res 2008; 157: 87–93.
  • Tolman AW, Kurtz MM: Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull 2012; 38: 304–315.
  • Vaddadi KS, Courtney P, Gilleard CJ et al.: A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 1989; 27: 313–323.
  • Vingerhoets WAM, Bloemen OJN, Bakker G et al.: Pharmacological interventions for the MATRICS cognitive domains in schizophrenia: what’s the evidence? In: Schmidt A, Borgwardt S (eds.): Neuropsychopharmacology of Psychosis: Relation of Brain Signals, Cognition and Chemistry. Frontiers Media SA, Lausanne 2015: 44–65.
  • Wen YT, Dai JH, Gao Q: Effects of Omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2014; 24: 470–475.
  • Wykes T, Huddy V, Cellard C et al.: A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011; 168: 472–485.
  • Zhang JP, Gallego JA, Robinson DG et al.: Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2013; 16: 1205–1218.
Document Type
review
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-55bbc656-9dab-4e9b-a68e-57becee5e02d
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.